p.100 抽出テキスト

Program). Am J Cardiol 2020;125:894–900. https://doi.org/10.1016/j. amjcard.2019.12.025 663. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017;69:2885–96. https://doi.org/10.1016/j.jacc. 2017.04.001 664. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818–28. https://doi.org/10.1016/S0140- 6736(16)31258-2 665. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patientreported quality of life: the RATE-AF randomized clinical trial. JAMA 2020; 324:2497–508. https://doi.org/10.1001/jama.2020.23138 666. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944–51. https:// doi.org/10.1016/j.jacc.2003.07.020 667. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451. https://doi.org/10.1136/ bmj.h4451 668. Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J 1999;20:1833–42. https://doi.org/10. 1053/euhj.1999.1747 669. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521–8. https://doi.org/10.1093/oxfordjournals.eurheartj. a060945 670. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29: 1149–53. https://doi.org/10.1097/00003246-200106000-00011 671. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F. Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr 2004;116:744–9. https://doi.org/10.1007/s00508-004-0264-0 672. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999–4008. https://doi.org/10. 1093/eurheartj/ehy555 673. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42:4731–9. https://doi.org/10.1093/eurheartj/ehab569 674. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27. https://doi.org/10.1056/NEJMoa1707855 675. Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389:1380–9. https://doi.org/10.1056/NEJMoa2306037 676. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation 2022;145:1693–704. https://doi.org/10.1161/ CIRCULATIONAHA.121.057095 677. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–74. https:// doi.org/10.1001/jama.2019.0693 678. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 2021;143: 1377–90. https://doi.org/10.1161/CIRCULATIONAHA.120.050991 679. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731. https://doi.org/10.1161/CIRCEP.119. 007731 680. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol 2017;70: 1949–61. https://doi.org/10.1016/j.jacc.2017.08.041 681. Pasqualotto E, Ternes CMP, Chavez MP, Polanczyk CA, Ferreira ROM, Nienkotter T, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: a meta-analysis. Heart Rhythm 2024;21:1604–12. https://doi.org/10.1016/j.hrthm.2024.04.098 682. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133: 1637–44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406 683. Chieng D, Sugumar H, Segan L, Tan C, Vizi D, Nanayakkara S, et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial. JACC Heart Fail 2023;11:646–58. https://doi.org/10. 1016/j.jchf.2023.01.008 684. Oraii A, McIntyre WF, Parkash R, Kowalik K, Razeghi G, Benz AP, et al. Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction: a systematic review and meta-analysis. JAMA Cardiol 2024;9:545–55. https://doi.org/10.1001/jamacardio.2024.0675 685. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31–8. https://doi.org/10.1161/CIRCEP.113.000806 686. Martens P, Augusto SN Jr, Erzeel J, Pison L, Mullens W, Tang WHW. Effects of atrial fibrillation ablation for heart failure with preserved ejection fraction: insights from CABANA. JACC Heart Fail 2025;13:785–94. https://doi.org/10. 1016/j.jchf.2025.01.029 687. Doehner W, Boriani G, Potpara T, Blomstrom-Lundqvist C, Passman R, Sposato LA, et al. Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association. Europace 2025;27:euaf019. https://doi.org/10.1093/europace/ euaf019 688. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet 2020;395:339–49. https://doi.org/10.1016/S0140- 6736(19)32994-0 689. Prasai P, Shrestha DB, Saad E, Trongtorsak A, Adhikari A, Gaire S, et al. Electric cardioversion vs. pharmacological with or without electric cardioversion for stable new-onset atrial fibrillation: a systematic review and meta-analysis. J Clin Med 2023;12:1165. https://doi.org/10.3390/ jcm12031165 690. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268–76. https://doi.org/10.1056/NEJMoa1109867 691. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781–8. https://doi.org/10.1056/NEJM199103213241201 692. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574–9. https://doi.org/10.1161/01.cir.98.23.2574 693. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110:607–13. https://doi.org/10.1016/j. amjcard.2012.04.034 694. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Eur Heart J 1992;13:1251–8. https://doi.org/10.1093/oxfordjournals.eurheartj. a060345 695. Bonfanti L, Annovi A, Sanchis-Gomar F, Saccenti C, Meschi T, Ticinesi A, et al. Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. Clin Exp Emerg Med 2019;6:64–9. https://doi.org/10.15441/ceem. 17.286 696. Chen S, Purerfellner H, Meyer C, Acou WJ, Schratter A, Ling Z, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J 2020;41:2863–73. https://doi.org/10.1093/ eurheartj/ehz443 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026